Aligning CGT ambition with manufacturing reality

In cell and gene therapy, the programmes that run to plan are usually the ones where development and manufacturing decisions were made together from the start

You need to be a subscriber to read this article.
Click here to find out more.

Cell and gene therapy timelines are often set by ambition before the manufacturing work is understood.

Aligning CGT ambition with manufacturing reality

Jon Alberdi, CEO, and Marie Fertin, Chief Technological Innovation Officer, of VIVEBiotech, tell Dr Kevin Robinson (KSR) why sponsors should engage a CDMO early, share interface risks collaboratively and build development plans around process data.

Their practical advice helps developers to close the gap between what a programme aims to achieve and what manufacturing can reliably deliver.

KSR: At what stage should sponsors begin engaging CDMOs?

VIVEBiotech: The right time to bring in a CDMO is before key development decisions become difficult to reverse.

Early engagement gives the manufacturing partner a chance to assess how vector design choices could affect process development, product quality and the regulatory path before those choices are locked in. 

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.

You may also like